Infectologia

Uma análise da mortalidade de 114.000 pessoas infectadas pelo SARS-CoV-2 na Escócia revelou que a efetividade da vacina contra morte pela variante Delta foi de 90% para a Pfizer e 91% para a AstraZeneca.

21 Out, 2021 | 11:35h

BNT162b2 and ChAdOx1 nCoV-19 Vaccine Effectiveness against Death from the Delta Variant – New England Journal of Medicine

---

Um estudo de caso-controle mostrou que a vacinação contra Covid-19 no início da gestação não esteve associada a risco aumentado de aborto no primeiro trimestre.

21 Out, 2021 | 11:34h

Covid-19 Vaccination during Pregnancy and First-Trimester Miscarriage – New England Journal of Medicine

Conteúdos relacionados:

Editorial: Covid-19 treatments and vaccines must be evaluated in pregnancy.

Cohort study: Vaccinated pregnant patients had 90% lower risk of severe or critical Covid-19 compared with unvaccinated pregnant patients.

Two observational studies suggest spontaneous abortion is not increased following COVID-19 mRNA vaccination during pregnancy.

Study shows high effectiveness of the Pfizer mRNA COVID-19 vaccine in pregnancy.

5 Crucial Things to Know About COVID-19 Vaccines and Pregnancy.

CDC Guidance: Pregnant people should be vaccinated against COVID-19.

ACOG and SMFM Recommend COVID-19 Vaccination for Pregnant Individuals – “ACOG encourages its members to enthusiastically recommend vaccination to their patients.”

Cohort study: Pfizer/BioNTech COVID vaccine associated with 78% lower risk of Covid-19 in pregnancy.

---

Pneumonia por COVID-19: fisiopatologia e tratamento.

21 Out, 2021 | 11:30h

COVID-19 pneumonia: pathophysiology and management – European Respiratory Review

---

FDA autoriza o uso de doses de reforço das vacinas da Moderna e da Johnson & Johnson, e afirma que misturar e combinar é OK.

21 Out, 2021 | 11:29h

FDA authorizes booster doses of Moderna and Johnson & Johnson vaccines, says mix and match OK – CNN

Ver também:

FDA OKs mixing COVID vaccines; backs Moderna, J&J boosters – Associated Press

FDA OKs Moderna, J&J boosters, along with ‘mix and match’ approach – NBC News

---

Em vez de quarentena para estudantes expostos à Covid, algumas escolas estão tentando “testar-para-ficar”.

21 Out, 2021 | 11:27h

Instead of quarantine for Covid-exposed students, some schools are trying test-to-stay – CNN

Conteúdos relacionados:

Cluster RCT: Daily contact testing of school-based contacts was non-inferior to self-isolation for control of COVID-19 transmission.

Kids are losing school days to quarantines. Here’s a way to keep them in classrooms – “Test-to-stay could dramatically reduce close contact quarantines”.

Opinion | Data from routine Covid testing can help schools stay open this year.

---

Estudo do CDC | Vacina da Pfizer mostrou 93% de efetividade contra internações por Covid-19 entre crianças de 12 a 18 anos.

20 Out, 2021 | 12:12h

Effectiveness of Pfizer-BioNTech mRNA Vaccination Against COVID-19 Hospitalization Among Persons Aged 12–18 Years — United States, June–September 2021 – CDC Morbidity and Mortality Weekly Report

 

Comentário no Twitter (fio – clique para saber mais)

Vaccination reduced the risk of hospitalization among 12–18-year-olds by 93%, according to a new CDC study. No vaccinated adolescents died or were admitted to the ICU.

— Dr. Tom Frieden (@DrTomFrieden) October 19, 2021

 

---

Estudo randomizado | Interferon não melhora os desfechos de adultos internados com COVID-19.

20 Out, 2021 | 12:10h

Comunicado de imprensa: Interferon does not improve outcomes for hospitalized adults with COVID-19 – NIH News Releases

Estudo original: Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial – The Lancet Respiratory Medicine

---

Estudo de coorte | A efetividade da vacinação heteróloga AstraZeneca (AZ)/mRNA foi mais significativa (68%) do que a vacinação homóloga AZ/AZ (50%) contra Covid-19 sintomática na Suécia.

20 Out, 2021 | 12:08h

Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study – The Lancet Regional Health Europe

Comentário: High effectiveness of mix-and-match COVID-19 vaccines – UMEA University

Conteúdos relacionados:

Study evaluated several heterologous SARS-CoV-2 vaccine regimens; no efficacy data but there was increased antibody production on study days 15 and 29 after booster shots from Moderna and Pfizer.

A primer on what we know about mixing and matching Covid vaccines.

Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination.

RCT: Safety and immunogenicity of heterologous vs. homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine.

Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination.

Heterologous Oxford–AstraZeneca and Moderna Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

Heterologous Oxford–AstraZeneca and BioNTech/Pfizer Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

[Preprint] Mixing Covid jabs has good immune response, study finds – “The Com-Cov trial looked at the efficacy of either two doses of Pfizer, two of AstraZeneca, or one of them followed by the other. All combinations worked well, priming the immune system”.

Phase 2 RCT: Immunogenicity and reactogenicity of a Pfizer-BioNTech booster in patients that have received a single dose of AstraZeneca vaccine – “BNT162b2 (Pfizer) given as a second dose in individuals prime vaccinated with ChAdOx1-S (AstraZeneca) induced a robust immune response, with an acceptable and manageable reactogenicity profile”.

Lab study shows heterologous AstraZeneca/Pfizer vaccination produces strong immune response against SARS-CoV-2 Delta variant.

Lab study shows a heterologous AstraZeneca + Pfizer immunization strategy provides stronger immunogenicity against Covid compared to homologous AZ + AZ or Pfizer + Pfizer strategies.

RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.

 

Comentário no Twitter

Study from Sweden assessing heterogenous vaccination in 3,445,061 individuals who received AZ as the first dose and either #pfizer, #moderna, or #AZ as second dose showed the following vaccine effectiveness:

AZ/Pfizer- 67%
AZ/Moderna- 79%
AZ/AZ- 50%https://t.co/UN0pey2kJ2

— Yan Leyfman, MD (@YLeyfman) October 19, 2021

 

---

Deve-se misturar e combinar a dose de reforço da vacina?

20 Out, 2021 | 12:06h

Should You Mix and Match Your Booster Shot? – The Atlantic

Conteúdos relacionados:

Study evaluated several heterologous SARS-CoV-2 vaccine regimens; no efficacy data but there was increased antibody production on study days 15 and 29 after booster shots from Moderna and Pfizer.

A primer on what we know about mixing and matching Covid vaccines.

Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination.

RCT: Safety and immunogenicity of heterologous vs. homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine.

Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination.

Heterologous Oxford–AstraZeneca and Moderna Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

Heterologous Oxford–AstraZeneca and BioNTech/Pfizer Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

[Preprint] Mixing Covid jabs has good immune response, study finds – “The Com-Cov trial looked at the efficacy of either two doses of Pfizer, two of AstraZeneca, or one of them followed by the other. All combinations worked well, priming the immune system”.

Phase 2 RCT: Immunogenicity and reactogenicity of a Pfizer-BioNTech booster in patients that have received a single dose of AstraZeneca vaccine – “BNT162b2 (Pfizer) given as a second dose in individuals prime vaccinated with ChAdOx1-S (AstraZeneca) induced a robust immune response, with an acceptable and manageable reactogenicity profile”.

Lab study shows heterologous AstraZeneca/Pfizer vaccination produces strong immune response against SARS-CoV-2 Delta variant.

Lab study shows a heterologous AstraZeneca + Pfizer immunization strategy provides stronger immunogenicity against Covid compared to homologous AZ + AZ or Pfizer + Pfizer strategies.

RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.

---

[Preprint] Estudo observacional no Brasil mostrou que a efetividade ajustada da vacina da J&J foi de 50,9% contra Covid-19 sintomática, 72,9% para internações, 92,5% para admissão em UTI, 88,7% para ventilação mecânica e 90,5% para morte.

20 Out, 2021 | 12:05h

Vaccine effectiveness of Ad26.COV2.S against symptomatic COVID-19 and clinical outcomes in Brazil: a test-negative study design – medRxiv

---